Akari Therapeutics (AKTX) Convertible Debt (2024 - 2026)

Akari Therapeutics has disclosed Convertible Debt across 3 years of filings, most recently posting $683000.0 for Q1 2026.

• Convertible Debt for Q1 2026 came in at $683000.0, down 2.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $683000.0 (down 2.43% YoY), and the FY2025 annual result was $673000.0, down 3.86% from the prior year.
• Convertible Debt came in at $683000.0 for Q1 2026 at Akari Therapeutics, up from $673000.0 in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $700000.0 in Q4 2024 to a low of $663000.0 in Q3 2025.
• The 3-year median for Convertible Debt is $691500.0 (2024), against an average of $686500.0.
• Across the five-year window, Convertible Debt dropped 3.86% in 2025 and fell 2.43% in 2026, its largest moves.
• Akari Therapeutics' Convertible Debt stood at $700000.0 in 2024, then retreated by 3.86% to $673000.0 in 2025, then advanced by 1.49% to $683000.0 in 2026.
• The last three Convertible Debt figures came in at $683000.0 (Q1 2026), $673000.0 (Q4 2025), and $663000.0 (Q3 2025), per Business Quant data.